SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitfarms Ltd. (Canada) engages in the business of mining cryptocurrency. The firm is also involved in the ownership and operation of server farms comprised of computers designed for the purpose of validating transactions on the Bitcoin blockchain. The company was founded by Emiliano Joel Grodzki and Nicolas Bonta in 2017 and is headquartered in Toronto, Canada.

Bitfarms Ltd.

Bitfarms ($BITF) is trending as discussions revolve around its strategic shift toward AI and high-performance computing, alongside a recently announced offering. The community is weighing the potential impact of this move, with some viewing it as a positive step for long-term growth, while others express concerns about potential dilution. Investors are actively debating the implications of the offering and the company's future prospects in the evolving landscape of AI and cryptocurrency.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Praxis Precision Medicines is trending due to positive topline results from Phase 3 trials of ulixacaltamide HCl for essential tremor, sparking significant pre-market gains and heavy trading volume. The community is focused on the high institutional ownership potentially leading to a short squeeze, with some speculating on price targets. This movement occurs within the context of the essential tremor treatment space, where there is a large unmet need for effective therapies.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending due to a lawsuit from Singapore's GIC alleging inflated revenue figures, sparking debate about its impact. The community is divided, with some viewing it as a buying opportunity amidst recycled headlines and others expressing concern. Discussions also include delivery numbers, battery swap technology, and the broader context of Chinese EV competition.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending as analysts update their ratings, citing a clear path to growth and potential investor sentiment improvement, especially with the company's AI integrations. Community discussions revolve around potential revival of the AI software/enterprise trade and possible short-term trading opportunities. The stock also garnered attention following Salesforce and Google's deepened partnership with Gemini integration, further emphasizing the company's focus on AI.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor is trending after reporting strong Q3 earnings, driven by surging AI chip demand, and raising its 2025 revenue growth outlook. Community members are discussing the company's impressive profit increase and potential for further gains, while also noting geopolitical risks. Some analysts are raising price targets, citing TSMC's key role in the AI boom and strong guidance.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

SPDR Gold Shares ETF ($GLD) is trending as gold prices reach record highs, sparking debate about a potential bubble. While some community members foresee a continued surge driven by economic uncertainty and central bank buying, others anticipate a sharp correction, citing overbought conditions. Discussions revolve around shorting opportunities versus long-term bullish sentiment amidst global economic concerns.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as community members debate its valuation and potential for a short squeeze, with some citing insider selling as a cause for concern. Discussions include potential catalysts for movement, such as earnings and possible offerings, amid speculation about the future of quantum computing stocks. Bears and bulls continue to clash over the stock's direction and long-term potential.

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

ABAT is trending due to the termination of a DOE grant for its lithium hydroxide project, leading to a significant price drop and high trading volume. While the company is appealing the decision and states the project will continue unchanged, the community is debating the impact of the lost funding and potential need for alternative financing. Some investors view the dip as a buying opportunity, citing the company's long-term potential and strategic importance in the domestic battery technology sector.

Veritone, Inc. engages in the provision of artificial intelligence (AI) computing solutions to media and entertainment, government, and legal and compliance industries. It operates through the following segments: Advertising, aiWARE SaaS Solutions, and aiWARE Content Licensing and Media Services. The Advertising segment places advertisements for clients, primarily with radio broadcasters, podcasters and digital media producers. The aiWARE SaaS Solutions segment offers solutions through a combination of its direct sales force and indirect channel partners, such as value-added resellers (VARs), distributors, system integrators, managed services providers, and referral partners. The aiWARE Content Licensing and Media Services segment sells and markets activities relating to its digital content licensing services business through its direct sales force. The company was founded by Chad Edward Steelberg and Ryan S. Steelberg on June 13, 2014 and is headquartered in Denver, CO.

Veritone Inc

Veritone (VERI) is trending due to a registered direct offering of $75 million, leading to community discussion about dilution and management's timing. While some investors express concerns about the offering's impact on share value, others view it as a necessary step for growth and debt repayment, emphasizing the company's long-term potential in the AI sector. Community members are actively debating whether this dip presents a buying opportunity or signals further downside.

Microvast Holdings, Inc. is an advanced battery technology company. It engages in the business of designing, developing, and manufacturing battery components and systems primarily for electric commercial vehicles and utility-scale energy storage systems. The company was founded by Yang Wu on October 12, 2006 and is headquartered in Stafford, TX.

Microvast Holdings Inc

MVST is trending as investors discuss its valuation relative to peers and potential catalysts like earnings and expansion plans. Community members are pointing to potential short squeezes and institutional buying, while also debating the company's ties to China. Overall, the discussion revolves around whether the stock is undervalued and poised for further gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Quantum BioPharma Ltd. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights QNTM

The DJS Law Group announces that it is investigating claims on behalf of investors of Quantum BioPharma Ltd. (Quantum BioPharma or the Company) (NASDAQ: QNTM) for violations of the securities laws...

QNTM Investors Have Opportunity to Join Quantum BioPharma Ltd. Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quantum BioPharma Ltd. (Quantum BioPharma or the Company...

Quantum BioPharma (QNTM) on Monday announced that it has signed an agreement with a leading contract development and manufacturing organization to manufacture an oral drug formulation of Lucid-MS.The agreement was signed through Quantum’s subsidiary, Huge Biopharma Australia Pty. Quantum, however, did not name the contract manufacturer.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/11/3130819/0/en/Quantum-BioPharma-Signs-Agreement-to-Manufacture-Oral-Drug-Formulation-of-its-Potential-Breakthrough-Drug-Lucid-21-302-Lucid-MS-for-Use-in-its-Upcoming-Phase-2-Multiple-Sclerosis-T.html">intends</a> to study the oral formulation of Lucid-MS in a mid-stage clinical trial and test its efficacy on humans as a possible treatment for people to regain mobility lost with multiple sclerosis (MS).Multiple Sclerosis is a chronic, often disabling, autoimmune disease that disrupts communication between the brain and other parts of the body. The symptoms include difficulty in walking, blurred vision, and altered sensations in limbs or face. In MS, the body's immune system mistakenly attacks healthy tissue, damaging the myelin sheath or the protective covering of nerve fibers.Lucid-MS is a patented chemical entity shown to prevent and reverse myelin degradation in preclinical models. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/QNTM">QNTM</a> fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume fell from ‘extremely high’ to ‘high’ levels. Shares of the company rose 4% in the pre-market session at the time of writing.Quantum said that numerous animal models over the past decade showed Lucid-MS helped those animals regain their ability to walk. “We are pleased to announce that we have signed this agreement with a leading CDMO to develop and manufacture an oral formulation of Lucid-MS. This marks an important step in the clinical development of Lucid-MS as we prepare the Investigational New Drug (IND) application with the FDA and prepare for our upcoming Phase 2 trial of Lucid-21-302 in MS,” said Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma.QNTM stock is up by 694% this year and by about 246% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/paramount-acquires-ufc-rights-for-7-7-billion-7-years-skydance-merger/chruxI6RdIu">Paramount Acquires UFC Rights For $7.7 Billion In A 7-Year Deal, Days After Skydance Merger</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Why Is Quantum BioPharma In The News Today? Here’s An Important Update On Its Multiple Sclerosis Investigational Drug

The company intends to study the oral formulation of Lucid-MS in a mid-stage clinical trial and test its efficacy on humans as a possible treatment for people to regain mobility lost with multiple sclerosis (MS).

Equity

The company intends to study the oral formulation of Lucid-MS in a mid-stage clinical trial and test its efficacy on humans as a possible treatment for people to regain mobility lost with multiple sclerosis (MS).


Quantum BioPharma drew increased retail buzz on Monday following its announcement of a new $1 million Bitcoin and cryptocurrency investment, which increased its crypto holdings to $4.5 million.The company’s shares climbed 19.61% to close at $12.26 on Monday before easing 2.85% to $11.91 in after-hours trading.The board-sanctioned investment supports the company’s established strategy of employing digital assets to protect against currency fluctuations while generating potential shareholder value.&nbsp;Quantum BioPharma confirmed that all digital assets are secured by a certified custodian and that future funding activities could use cryptocurrency.The company plans to modify its portfolio holdings according to current market trends.Quantum owns 20.11% of Celly Nutrition Corp., which sells the over-the-counter Unbuzzd product and pays Quantum royalties up to $250 million before starting perpetual 3% royalties.Meanwhile, its unit, Lucid Psycheceuticals, works on the preclinical multiple sclerosis therapy, Lucid-MS.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 4,200% increase in 24-hour message volume.One user noted that the stock remains under the radar, suggesting&nbsp;it is still in its early stages despite growing interest.&nbsp;<stembedurl>https://stocktwits.com/Bull93/message/615150520</stembedurl>Another pointed out that the stock has posted gains while maintaining relatively low trading volume, describing the move as “steady.”<stembedurl>https://stocktwits.com/Kerrz/message/615138127</stembedurl>The stock has surged over 200% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Portrait of a doctor woman on the background of stock charts. | Image source: Getty Images

Quantum BioPharma Stock Pops 20%, Retail Bullish Sentiment Builds After $1M Crypto Holdings Boost

The company increased its Bitcoin and cryptocurrency holdings to $4.5 million, reinforcing its strategy to hedge against currency fluctuations and improve shareholder value. 

Nasdaq-listed shares of Quantum BioPharma (QNTM) surged 15% on Wednesday after the company<a target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=5588894292867643"> said</a> its licensee, Celly Nutrition Corporation, has released a new format of its alcohol detox product that could be sold in convenience, liquor, and drug stores across the United States.Celly Nutrition is behind unbuzzd, a beverage that restores mental clarity and reduces symptoms of intoxication and hangovers. It has now released a new ready-to-mix powder stock version of the product, which is sold in packs of three, eight, or 18.Quantum BioPharma invented unbuzzd and spun out its over-the-counter version to Celly Nutrition.As part of the agreement between the two companies, Celly Nutrition has to pay 7% royalty on sales of unbuzzd to Quantum until payments total $250 million.Once $250 million is reached, the royalty drops to 3% in perpetuity, the company said.Quantum Biopharma has a 25.71% stake in Celly Nutrition as of June 30.John Duffy, CEO of Celly Nutrition, said that distribution of unbuzzd at popular brick and mortar stores is expected to be a “key growth driver” for the product.“The 8-pack display box enhances unbuzzd’s package evolution, meeting various consumer needs and accelerating retail availability across the United States. This new format aims to boost sales and profits for retailers in the estimated $2.1 billion global hangover cure products market,” Duffy added.The company said that the 8-pack box of the product is also available for purchase on Amazon and on unbuzzd’s website.On Stocktwits, retail investor sentiment surrounding Quantum BioPharma dipped from ‘bullish’ to ‘neutral’ territory while message volume dropped from ‘extremely high’ to ‘low’ over the past 24 hours.<figure class="image"><img style="aspect-ratio:648/154;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_26_at_12_49_36_PM_png_41938dc223.webp" alt="QNTM's Sentiment Meter and Message Volume as of 12:45 p.m. ET on March 26, 2025 | Source: Stocktwits" width="648" height="154"><figcaption>QNTM's Sentiment Meter and Message Volume as of 12:45 p.m. ET on March 26, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/QNTM">Quantum BioPharma shares</a> have gained over 65% this year but fell over 80% in the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/rivian-spins-off-micromobility-business-into-new-company-also/chJbT8iRb3m">Rivian Spins Off Micromobility Business Into New Company ‘Also’: Retail’s Elated</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

Quantum BioPharma Stock Soars After Licensee Celly Nutrition Releases New Format Of Alcohol Detox Product – Retail Shrugs It Off

Celly Nutrition has to pay 7% royalty on sales of alcohol detox product unbuzzd to Quantum until payments total $250 million and 3% royalty afterwards. 

Shares of Quantum BioPharma Ltd. slipped premarket Friday, but as of Thursday's close, the stock was on track for a staggering 366% weekly gain.Despite the rally, a Stocktwits poll revealed that 55% of retail traders missed the move, while 26% said they profited and "crushed it." Meanwhile, 11% reported losing money on the stock.<figure class="image"><img style="aspect-ratio:1316/762;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/QNTM_rally_Stocktwits_poll_on_Feb_7_4a24f41217.png" alt="QNTM rally Stocktwits poll on Feb 7.png" width="1316" height="762"><figcaption>QNTM rally Stocktwits poll on Feb 7</figcaption></figure>The surge followed Tuesday's announcement that Quantum had completed a double-blind, randomized, placebo-controlled clinical trial evaluating its dietary supplement, Unbuzzd, for alcohol metabolism.Key findings&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/qntm-surges-after-unbuzzd-trial-shows-blood-alcohol-reduction/chPr5suRAs">showed</a> that Unbuzzd reduced blood alcohol concentration (BAC) over 40% faster within 30 minutes compared to control subjects, with effects lasting throughout the four-hour measurement period.&nbsp;The supplement further reduced headache severity by 67% at four hours and continued to ease cognitive and physical impairment up to eight hours after consumption.Adding to the bullish sentiment, Quantum on Thursday said that Celly Nutrition Corp., the company behind Unbuzzd, has engaged a leading New York investment bank to raise up to $10 million and explore an initial public offering on a major U.S. exchange, pending regulatory approval.&nbsp;Quantum retains a 25.71% ownership stake in Celly Nutrition and earns a 7% royalty on Unbuzzd sales until total payments reach $250 million, after which royalties drop to 3% in perpetuity.In December, Quantum BioPharma announced it had purchased $1 million worth of Bitcoin and other cryptocurrencies as part of its strategic efforts.&nbsp;The stock's meteoric rise has driven a surge in retail interest. As of Thursday's close, Stocktwits message volume about Quantum skyrocketed 1,030 times over the past week,, while the company's follower count jumped nearly 19%.&nbsp;Sentiment on the platform remains 'extremely bullish' compared to a week ago.According to Koyfin data, Quantum ended the September quarter with $6.61 million in cash and investments and a total debt of approximately $370,000.&nbsp;The stock has gained nearly 18% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Quantum BioPharma Heads For Best Week Ever — But Most Retail Traders Lament Missing Out On The Surge

The company has attracted heavy attention after its dietary supplement, Unbuzzd, showed that it can reduce blood alcohol concentration rapidly in a clinical trial. 

Shares of Quantum BioPharma surged nearly 55% early Tuesday, hitting over a month's high and fueling retail enthusiasm. The stock is also on track for its best session in almost six months.The rally comes after the company announced the completion of a double-blind, randomized, placebo-controlled clinical trial evaluating its dietary supplement, Unbuzzd, for alcohol metabolism.&nbsp;Key findings include:<ul style="list-style-type:square;"><li>Unbuzzd reduced blood alcohol concentration (BAC) over 40% faster within 30 minutes compared to control subjects. This effect persisted throughout the four-hour measurement period.</li><li>Participants reported feeling more alert and made fewer cognitive errors just 30 minutes after consuming unbuzzd, with results significantly outperforming placebo.</li><li>Effective Hangover Relief: unbuzzd led to a 67% reduction in headache severity at four hours and continued to ease cognitive and physical impairment up to eight hours after consumption.</li><li>The formula was well-tolerated, with no reported adverse effects among study participants.</li></ul>CEO Zeeshan Saeed said, "Consumers now have the benefit of knowing that Unbuzzd can reduce alcohol intoxication, speed blood alcohol reduction, restore mental alertness, and help avoid the worst symptoms of a hangover."<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/QNTM_sentiment_and_message_volume_on_Feb_4_a88a27f782.png" alt="QNTM sentiment and message volume on Feb 4.png" width="1318" height="324"><figcaption>QNTM sentiment and message volume on Feb 4 as of 10:20 am ET | source: Stocktwits</figcaption></figure>Quantum's stock sentiment on Stocktwits surged to its highest level in a year, with a flood of bullish chatter.<stembedurl>https://stocktwits.com/etrade/message/602775346</stembedurl><stembedurl>https://stocktwits.com/Titan202/message/602775307</stembedurl>However, some skeptics raised concerns over missing details, such as the blood's phosphate levels and the testing center's name.Quantum BioPharma has a low float, with just 1.93 million shares outstanding. Trading volume Tuesday morning was nearly 350 times the daily average of 57,300.&nbsp;The stock's&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/qntm-stock-retail-following-surges/c7wPPHqRcm">following</a> on Stocktwits has increased by over 13% in the past three months.Quantum focuses on neurodegenerative and metabolic disorders, including alcohol misuse. Through its subsidiary, Lucid Psycheceuticals Inc., the company is advancing Lucid-MS, a patented compound targeting multiple sclerosis.Quantum invented Unbuzzd, which sells on Amazon and spun off its over-the-counter version to Celly Nutrition Corp., retaining a 25.71% stake as of June 30, 2024.&nbsp;The company also earns a 7% royalty on Unbuzzd sales until total payments reach $250 million, after which royalties drop to 3% in perpetuity.Quantum's stock has lost over 74% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Quantum BioPharma-backed Celly Nutrition's Unbuzzd

Quantum BioPharma Stock Soars As Unbuzzd Trial Shows Rapid Fall In Blood Alcohol Levels, Retail Frenzy Ensues

The company said it also led to a 67% reduction in headache severity at four hours and continued to ease cognitive and physical impairment up to eight hours after consumption.

<h3>What’s Happening?</h3>Quantum BioPharma Ltd. (NASDAQ: QNTM), a small biopharmaceutical company with an $8 million market cap, has launched a&nbsp;$700 million lawsuit&nbsp;against several of Wall Street’s largest financial institutions. Allegations center on "spoofing," a manipulative tactic that Quantum claims artificially suppressed its stock price, leading to massive losses for the company and its shareholders.The lawsuit, filed in the U.S. District Court for the Southern District of New York, names&nbsp;CIBC World Markets,&nbsp;RBC Dominion Securities, and other unnamed parties. The alleged spoofing occurred from&nbsp;January 2020 to August 2024, during which Quantum's stock price fell over&nbsp;98%, from over $460 per share (adjusted for splits) to just $7.55 by October 2024.Zeeshan Saeed, CEO of Quantum BioPharma, stated:<blockquote>“We believe that the Company and its shareholders have suffered immensely from the Defendants’ trading practices. We will use all means available to us to get justice for our shareholders.”</blockquote>The lawsuit alleges that these Wall Street giants prioritized their profits at the expense of Quantum's shareholders, distorting the market and eroding trust in financial fairness.<h3>Who Should Join and How to Get Involved</h3>Quantum BioPharma is encouraging its shareholders to&nbsp;join hands with the company by sharing their experiences and detailing how they may have been affected by the alleged stock price manipulation. By contributing their stories, shareholders can help&nbsp;strengthen Quantum's position as it seeks justice in its lawsuit against Wall Street institutions.To provide your input, go to&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.quantumbiopharma.com/quantum-biopharma-vs-banks">Quantum BioPharma's dedicated lawsuit page</a> and scroll to the bottom to find the form.Your participation can play a key role in building a stronger case and ensuring that Quantum's position is as robust as possible as it fights for fairness and accountability in the markets.<h3>The Legal Heavyweights Taking on Wall Street</h3>Successfully challenging Wall Street’s biggest banks requires the best in the business. Quantum BioPharma has enlisted two powerhouse law firms:&nbsp;Freedman Normand Friedland LLP and&nbsp;Christian Attar, both renowned for their expertise in securities litigation and market manipulation cases.<h4>Freedman Normand Friedland LLP: Delivering Historic Wins</h4>Based in New York, Miami, and Boston, Freedman Normand Friedland has a proven track record of securing massive settlements:<ul><li>$284 million in an antitrust settlement against top U.S. universities.</li><li>$140 million awarded by a jury in a 2021 securities case.</li></ul>Velvel Freedman, co-lead counsel on the Quantum case, stated:<blockquote>“Spoofing erodes trust in financial markets and is illegal. Our job is to ensure that Quantum BioPharma and its shareholders receive the justice they deserve.”</blockquote>Freedman’s extensive experience and the firm’s record of winning landmark cases make them an invaluable asset to Quantum’s fight.<h4>Christian Attar: 20 Years of Fighting Wall Street</h4>Christian Attar, based in Houston, Texas, has spent two decades taking on financial giants. Their team has recovered millions for companies impacted by stock manipulation, including cases involving&nbsp;Overstock.com and&nbsp;Taser International, both of which saw significant share price rebounds after their lawsuits.James Wes Christian, a partner at Christian Attar, added:<blockquote>“This could be one of the top five biggest spoofing cases we’ve ever handled. The evidence we’ve reviewed is compelling, and we’re confident in achieving a favorable outcome for Quantum and its shareholders.”</blockquote>The combined strength of these two firms, both working on a contingency basis (meaning they only get paid if they win), demonstrates their confidence in the evidence.<h3>Wall Street’s History of Skimming from Main Street</h3>Predatory practices by major financial institutions have long harmed smaller, retail investors. Spoofing—manipulating market prices by placing and canceling large fake orders—is just one of the tactics used to distort markets for their gain while leaving victims at a loss.In recent years, regulators have penalized some of the largest banks for engaging in such schemes, often with significant fines:<ul><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cftc.gov/PressRoom/PressReleases/7516-17">Citigroup (NYSE: C)</a> (2017) Was fined&nbsp;$25 million by the U.S. Commodity Futures Trading Commission (CFTC) for spoofing in the metals and Treasury futures markets.</li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cftc.gov/PressRoom/PressReleases/8260-20">J.P. Morgan (NYSE: JPM)</a> (2020) Paid a record&nbsp;$920 million for spoofing across the precious metals and Treasury markets, marking one of the largest spoofing penalties in history.</li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.finra.org/media-center/newsreleases/2023/finra-fines-bofa-securities-24-million-for-treasuries-spoofing-and-related-supervisory-failures">Bank of America (NYSE: BAC)</a> (2023) Was fined&nbsp;$24 million for spoofing-related violations that undermined market transparency and fairness.</li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bankingdive.com/news/td-28m-penalties-spoofing-scheme-doj-sec-finra/728558/">TD Securities (TSX: TD)</a> (2023) Faced penalties as part of a broader investigation into spoofing, with fines totaling&nbsp;$40 million for their role in market manipulation.</li></ul>While these fines appear substantial, they are often viewed as little more than&nbsp;the cost of doing business for major financial institutions. For retail investors and smaller companies, however, the consequences are far-reaching, including manipulated share prices, reduced confidence, and significant financial harm.This history highlights the urgent need for&nbsp;greater accountability and transparency in financial markets, ensuring that predatory practices like spoofing are no longer tolerated.<h3>Media Attention and Growing Coverage</h3>The lawsuit has captured the attention of major media outlets, with&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.theglobeandmail.com/business/article-quantum-biopharma-sues-over-alleged-stock-spoofing/">The Globe and Mail&nbsp;</a>publishing an in-depth article that highlights the case’s significance.The Globe and Mail article stated:<blockquote>“CEO and Co-Chairman Zeeshan Saeed explains that this isn’t just a shot in the dark—industry experts estimate that damages could exceed $1 billion for $QNTM.</blockquote>In addition,&nbsp;Agoracom, a leading platform for small-cap news, has featured the case in a detailed interview with Quantum executives. In the interview, CEO Zeeshan Saeed discusses how the alleged manipulation impacted the company’s stock price and its ability to raise capital.<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.youtube.com/watch?v=sxRNhzOXqPs">&nbsp;Watch the full Agoracom interview here</a>.Quantum’s bold legal move has also sparked discussions in online investor forums, where shareholders are voicing their support for the company’s efforts to hold Wall Street accountable.<h3>What It Could Mean for the Stock</h3>A successful outcome in Quantum BioPharma’s lawsuit could have a transformative impact on its stock. Here’s how the potential damages break down:- Potential Recovery: If Quantum recovers 25% of the $700 million claim, that equals&nbsp;$175 million.- After Legal Fees: Assuming half of the recovery is allocated to the lawyers, Quantum would still net&nbsp;$87.5 million.- Market Cap Impact: With an $8 million market cap, this would represent a&nbsp;10x increase, even before accounting for renewed investor confidence and market re-ratings.The prospect of such a windfall could attract new investors, and significantly boost Quantum’s valuation.&nbsp; Historical cases, such as those involving Overstock.com and Taser International, demonstrate how companies can achieve massive share price recoveries following litigation victories. These funds could also fund Quantum’s human clinical trials for their multiple sclerosis drug, Lucid-MS.&nbsp;<h3>Conclusion: A $4 Stock Fighting Back</h3>Quantum BioPharma’s lawsuit against Wall Street’s biggest banks is about more than just recovering damages—it’s a fight for fairness in the financial markets. With&nbsp;$700 million at stake, an&nbsp;$8 million market cap, and the backing of two of America’s most successful law firms, Quantum is taking a stand on behalf of its shareholders.This case represents a unique opportunity for investors. Should Quantum prevail, the upside could be immense, both for the company and for those who join the lawsuit to seek justice.&nbsp;<hr>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Do you have a stock tip or news story suggestion? Please email us at&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=5971807397151825">Invest@WealthyVC.com</a>.This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security. WealthyVC and our controlling entity 1000724287 Ontario Ltd have been compensated USD $20,000 for social media marketing and USD $7,500 per month for 3 months for investor relations by Quantum BioPharma Ltd.None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day’s closing price and the high of-day price during our promotional coverage.In preparing this publication, Wealthy VC has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Wealthy VC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Wealthy VC is not responsible for any claims made by the companies advertised herein, nor is Wealthy VC responsible for any other promotional firm, its program or its structure.<hr>This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

How This $4 Stock is Taking on Wall Street's Big Banks with a $700 Million Lawsuit

Two of America’s Most Prestigious Law Firms Team Up to Go After Several of Wall Street’s Biggest Banks on Behalf of Quantum BioPharma (NASDAQ: QNTM)—and Are So Confident, They Are Fronting the Legal Costs 

Exclusive X.com “Spaces” interview to StockTwits’ 1 million followers on the “The Daily Rip” show this Thursday, November 21st, 2024 at 9 AM Eastern Time. When investors think of the best-performing stocks in the market the first names that come to mind are big tech darlings like NVIDIA (NASDAQ: NVDA) and Amazon (NASDAQ: AMZN). But it's not them.Mentally rewind to the ‘90s and maybe it conjures up memories of Red Bull and an era of good music. A huge hit right off the bat, Red Bull created a new segment of functional beverages. This opened the floodgates for a number of drink companies that blew big tech out of the water with their stock returns in the decades to follow.&nbsp;This included&nbsp;Monster Beverage (NASDAQ: MNST) and&nbsp;Celsius Holdings (NASDAQ: CELU). From a price of&nbsp;$0.10 in&nbsp;2014 to its recent 52-week high of&nbsp;$99.62, Celsius Holdings has blown away most other stocks over the past 10 years with a 100,000% return, or 96% compounded annually. Investors could have turned $10,000 into nearly $10 million. And it was all because of one “hero ingredient.” Celsius energy drink boasts a scientifically proven formula that burns up to 140 calories per can. Pretty simple, right? This “category invention” playbook created $20 billion in shareholder value out of thin air.This same team from&nbsp;Celsius, including the&nbsp;ex-CEO Gerry David and&nbsp;ex-director, marketing guru and Shark Tank Shark Kevin Harrington are gearing up to do the same with&nbsp;Unbuzzd™. Unbuzzd™ is a rapid alcohol detoxification beverage, the first-to-market with a scientifically formulated powder stick and RTD beverage for this fast-growing consumer product category, expected to grow to&nbsp;$6.2 billion by 2030.&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_20_at_1_53_43_AM_1de2f2efc5.png" alt="Screenshot 2024-11-20 at 1.53.43 AM.png">&nbsp;Many companies have attempted to cure hangovers, but sell nothing more than modern-day snake oil. This company not only thinks it holds the key to hangovers but can also rapidly sober someone up, vastly increasing the market size. The applications are more vast than one can imagine especially when you consider the potential in-hospital application.&nbsp;The brainchild and portfolio company of&nbsp;Quantum BioPharma (NASDAQ: QNTM), Unbuzzd™ represents years of scientific research and formulation culminating in proprietary blend ingredients with one goal in mind—results—which will be detailed in its pending, double-blind, placebo-controlled clinical study, expected here in Q4.Watch Jason Sawyer,&nbsp;QNTM’s Head of Finance and M&amp;A this&nbsp;Thursday, November 21st, 2024 at 9 AM Eastern Time live on X.com Spaces hosted by StockTwits and its audience of more than 1 million followers. Jason will be discussing Quantum BioPharma’s upcoming clinical trial results for its alcohol detoxification drink, their team that was the driving force behind Celsius’ massive success, and how the company is flipping the script on multiple sclerosis drug development.Watch live at 9 AM eastern by accessing the live stream on Quantum BioPharma’s profile on Stocktwits&nbsp;<a href="https://stocktwits.com/symbol/QNTM">here</a>.&nbsp;&nbsp;&nbsp;<hr>&nbsp;This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security. WealthyVC and our controlling entity 1000724287 Ontario Ltd have been compensated USD $20,000 for social media marketing and USD $7,500 per month for 3 months for investor relations by Quantum BioPharma Ltd.None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements.&nbsp; Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage.This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

Come See How one “Hero Ingredient” Generated 100,000% Stock Gains and how the Same Team is Using the Same Playbook to Invent a new Beverage Segment    

Christian Attar Files Market Manipulation Case On Behalf of Quantum Biopharma

Christian Attar Files Market Manipulation Case On Behalf of Quantum Biopharma Christian Attar Files Market Manipulation Case On Behalf of Quantum Biopharma PR Newswire HOUSTON, Oct. 28, 2024 HOUSTON...

Quantum BioPharma Ltd. is a biopharmaceutical company, which engages in building a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. It operates through the Biopharmaceutical and Strategic Investments segments. The Biopharmaceutical segment focuses on furthering the research and development of the drug candidates and the development of a treatment for alcohol misuse for application in hospitals and other medical practices. The Strategic Investments segment is involved in the generation of returns and cash flow through the issuance of loans secured by residential property, with FSD Strategic Investments having a first or second collateral mortgage on the secured property. The company was founded by Thomas Fairfull, Zeeshan Saeed, and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Quantum BioPharma Ltd. - Ordinary Shares - Class B (Sub Voting)

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$15.21
Prev Close	$15.15
Open	$15.14
Dividend Yield	0.00%
50-Day Moving Average	$18.08
Beta	1.17
Avg. Volume	145,190.52
PE Ratio	-1.02

52-Week High	$38.25
52-Week Low	$2.70
Market Capitalization	$80.13M
EPS (Annual)	-$12.49
Price to Book	7.16
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

QNTM
Quantum BioPharma Ltd

Feed

News

Sentiment

Fundamentals

Info

Latest QNTM News

QNTMQuantum BioPharma Ltd